WuXi Biologics
WuXi Biologics - Discovery, Development, Manufacturing - CDMO - CMO. Spun out of WuXi AppTec.
Launch date
Employees
Market cap
AUD8.9b
Enterprise valuation
AUD7.5b (Public information from Sep 2024)
Share price
HKD12.32 2269.HK
Xuancheng Anhui (HQ)
Financials
Estimates*
| CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 5.6b | 10.3b | 15.3b | 17.0b | 17.9b | 20.2b | 23.0b |
| % growth | 41 % | 83 % | 48 % | 12 % | 5 % | 13 % | 14 % |
| EBITDA | 2.1b | 4.3b | 7.0b | 5.7b | 6.0b | 7.0b | 8.0b |
| % EBITDA margin | 37 % | 42 % | 46 % | 33 % | 33 % | 35 % | 35 % |
| Profit | 1.7b | 3.4b | 4.4b | 3.4b | 3.3b | 4.1b | 4.9b |
| % profit margin | 30 % | 33 % | 29 % | 20 % | 19 % | 20 % | 21 % |
| EV / revenue | 62.2x | 30.3x | 14.4x | 6.3x | 1.9x | 1.7x | 1.4x |
| EV / EBITDA | 169.4x | 72.0x | 31.6x | 18.9x | 5.8x | 4.9x | 3.9x |
| R&D budget | 304m | 502m | 683m | 786m | - | - | - |
| R&D % of revenue | 5 % | 5 % | 4 % | 5 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Corporate spinout | ||
* | N/A | - | |
| N/A | N/A | IPO | |
| Total Funding | - | ||
Related Content
Recent News about WuXi Biologics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by WuXi Biologics
Edit
exited
ACQUISITION by Dechra Pharmaceuticals Jul 2024
